BioSpace News Archive

Underwritten public offering of 5,500,000 shares of its common stock at a price to the public of $32.00 per share have exercised in full their option to purchase an additional 825,000 shares of common stock at the public offering price, less underwriting discounts and commissions

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq. announces that KSF has commenced an investigation into Iovance Biotherapeutics, Inc.

MiMedx Group, Inc. received written notification from the NASDAQ Stock Market that the Company is no longer in compliance with the NASDAQ Listing Rules since MiMedx has not yet filed its Form 10-K for the year ended December 31, 2017

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC, announces that KSF has commenced an investigation into Civitas Solutions, Inc. (NYSE: CIVI).

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC, announces that KSF has commenced an investigation into Lipocine Inc.

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) of DUPIXENT® (dupilumab) as an add-on maintenance treatment in certain adults and adolescents (12 years of age and older) with moderate-to-severe asthma.

Royal Philips and Hologic, Inc. announced a global partnership agreement to offer care professionals integrated solutions comprising diagnostic imaging modalities, advanced informatics and services for screening, diagnosis and treatment of women across the world.

Saranas has been invited to present at the 21st Cardiovascular Research Technologies (CRT18) annual conference, March 6, 2018, in Washington, DC.

EyeSouth is an eye care-focused physician services organization formed by Shore Capital Partners, a leading lower middle market healthcare private equity firm.

Glaukos is ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma